Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Germany

Hospital of the University of Munich, Munich

Klinikum Rechts der Isar of the Technical University Munich, Munich

Würzburg University Hospital, Würzburg